Showing 1 - 4 results of 4 for search 'Francesca Satolli', query time: 0.01s Refine Results
  1. 1
    Efficacy and safety of adalimumab biosimilar GP2017 in a 24-month treatment period for plaque psoriasis: real-life experience from Emilia-Romagna centers, Italy

    Efficacy and safety of adalimumab biosimilar GP2017 in a 24-month treatment period for plaque psoriasis: real-life experience from Emilia-Romagna centers, Italy by Marco May Lee, Vito Di Lernia, Francesca Peccerillo, Federico Bardazzi, Michela Tabanelli, Michela Ricci, Davide Melandri, Monica Corazza, Francesca Satolli, Andrea Conti

    Published 2025-07-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Effectiveness of Tildrakizumab 200 mg in Moderate-to-Severe Plaque Psoriasis: A Multicenter Real-World Study Analyzing Patient Outcomes by Weight, PASI, BMI, and Previous Therapies

    Effectiveness of Tildrakizumab 200 mg in Moderate-to-Severe Plaque Psoriasis: A Multicenter Real-World Study Analyzing Patient Outcomes by Weight, PASI, BMI, and Previous Therapies... by Emanuele Trovato, Tommaso Bianchelli, Giulia Odorici, Aldo Cuccia, Vito Giuseppe Di Lernia, Claudia Lasagni, Marco Manfredini, Massimiliano Nicolini, Giulia Rech, Francesca Satolli, Alessandra Cartocci, Federico Bardazzi, Anna Campanati

    Published 2025-05-01
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    Comparative effectiveness of tildrakizumab 200 mg versus tildrakizumab 100 mg in psoriatic patients with high disease burden or above 90 kg of body weight: a 16-week multicenter retrospective study – IL PSO (Italian landscape psoriasis)

    Comparative effectiveness of tildrakizumab 200 mg versus tildrakizumab 100 mg in psoriatic patients with high disease burden or above 90 kg of body weight: a 16-week multicenter re... by Luigi Gargiulo, Luciano Ibba, Ruggero Cascio Ingurgio, Piergiorgio Malagoli, Fabrizio Amoruso, Anna Balato, Federico Bardazzi, Pina Brianti, Giovanna Brunasso, Martina Burlando, Anna E. Cagni, Marzia Caproni, Carlo G. Carrera, Andrea Carugno, Francesco Caudullo, Aldo Cuccia, Paolo Dapavo, Eugenia V. Di Brizzi, Valentina Dini, Francesca M. Gaiani, Paolo Gisondi, Claudio Guarneri, Claudia Lasagni, Gaetano Licata, Francesco Loconsole, Angelo V. Marzano, Matteo Megna, Santo R. Mercuri, Maria L. Musumeci, Diego Orsini, Simone Ribero, Valentina Ruffo Di Calabria, Francesca Satolli, Davide Strippoli, Massimo Travaglini, Emanuele Trovato, Marina Venturini, Leonardo Zichichi, Mario Valenti, Antonio Costanzo, Alessandra Narcisi

    Published 2024-12-01
    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    Optimizing Tildrakizumab Dosing in Psoriasis: A 52-Week Multicenter Retrospective Study Comparing 100 mg and 200 mg—IL PSO (Italian Landscape Psoriasis)

    Optimizing Tildrakizumab Dosing in Psoriasis: A 52-Week Multicenter Retrospective Study Comparing 100 mg and 200 mg—IL PSO (Italian Landscape Psoriasis) by Mario Valenti, Luciano Ibba, Sara Di Giulio, Luigi Gargiulo, Piergiorgio Malagoli, Anna Balato, Federico Bardazzi, Francesco Loconsole, Martina Burlando, Anna E. Cagni, Norma Cameli, Carlo G. Carrera, Andrea Carugno, Aldo Cuccia, Paolo Dapavo, Eugenia V. Di Brizzi, Valentina Dini, Maria C. Fargnoli, Francesca M. Gaiani, Claudio Guarneri, Claudia Lasagni, Gaetano Licata, Angelo V. Marzano, Matteo Megna, Santo R. Mercuri, Alessandra Michelucci, Maria L. Musumeci, Diego Orsini, Romina Ortega, Luca Potestio, Luca Rapparini, Simone Ribero, Francesca Satolli, Davide Strippoli, Emanuele Trovato, Marina Venturini, Leonardo Zichichi, Pina Brianti, Antonio Costanzo, Alessandra Narcisi

    Published 2025-04-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: